LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Alcobra, Ltd. (“Alcobra” or the “Company”) (Nasdaq: ADHD). Investors who purchased or otherwise acquired shares between August 13, 2015 and January 17, 2017 inclusive (the "Class Period") are encouraged to contact the Firm in advance of the April 18, 2017 lead plaintiff motion deadline.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
Alcobra is a biopharmaceutical company that develops and sells oral drug candidates. On January 17, 2017, Alcobra revealed that the Company's attention deficit hyperactivity disorder drug, Metadoxine Extended Release, was unsuccessful in reaching its primary endpoint during a Phase 3 trial. When this information was released to the investing public, the value of Alcobra declined, causing investors severe harm.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.